Bioiberica Approves Its Combined Drug for Osteoarthritis in Five More European Countries
Bioiberica's combination of chondroitin sulphate and glucosamine hydrochloride, a slow action drug to treat osteoarthritis symptoms, was approved as an ethical drug in France, Austria, Hungary, Poland, and Finland through a mutual recognition process from Spain.
‘This approval confirms that Drug Agencies from different countries attest to the effectiveness and safety of the combination of pharmaceutical grade chondroitin sulphate and glucosamine hydrochloride. This drug has proven to reduce pain and improve mobility in people affected by knee osteoarthritis which, due to its safety profile, could also be used as an alternative by those patients with cardiovascular or gastrointestinal problems who should not be prescribed anti-inflammatory drugs chronically’, stated Dr Juan Gispert, Bioiberica's R&D director .
The principle study that guarantees its effectiveness is the MOVES clinical trial , published in the Annals of the Rheumatic Diseases, which concludes that the combination of chondroitin sulphate and glucosamine has an effectiveness comparable to the anti-inflammatory drug celecoxib after six months of treatment in patients with osteoarthritis and moderate to severe pain. It was observed that the combination of these two drugs relieves pain in a clinically relevant way. It also improves functional capacity, stiffness, relieves inflammation and joint effusion.
With these new approvals, a total of six European countries have approved Bioiberica brand’s combination of chondroitin sulphate and glucosamine hydrochloride. This year, the company plans to sign licensing and distribution agreements with companies specialised in the osteoarticular field to launch the product in the five countries where the drug was recently approved.
Bioiberica is the first European producer of chondroitin sulfate and international leader in joint health and chondroprotection thanks to a constant dedication and commitment to science and research. Vertically integrated, from the active ingredient to the finished product, Bioiberica offers its customers all their medical, scientific and commercial knowledge for the joint development of the market.
Alba Soler i Conangla, +34 93 490 49 08
PR- Corporate Communications Director
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
SMARTSTREAM-TECHNOLOGIES24.10.2018 01:03 | pressemeddelelse
Coronation Fund Managers Goes Live with SmartStream’s Corporate Actions Solution
FL-AERSALE23.10.2018 23:49 | pressemeddelelse
EASA Approves AerTrak ADS-B Out System for Boeing 737 NG Series Aircraft
PA-GREENE-TWEED23.10.2018 23:02 | pressemeddelelse
Greene Tweed Receives Patent for Rapid Gas Decompression-Resistant Fluoroelastomers and Molded Articles
MORINAGA-MILK-INDUSTRY23.10.2018 20:02 | pressemeddelelse
Morinaga Milk Study Suggests Infant-Type Human-Residential Bifidobacteria May Benefit Infant Health by Improving Digestion of Peptides in Milk and Grains
MYPOS-EUROPE-LTD23.10.2018 18:24 | pressemeddelelse
myPOS Founder Christo Georgiev Announces Two Upcoming myPOS Stores in Barcelona and Paris
MYPOS23.10.2018 18:13 | pressemeddelelse
Christo Georgiev Announces the Arrival of myPOS AppMarket
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum